Active substance
Soybean oil
- US FDA 13
- Health Canada 1
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| INTRALIPID 20% | 20% | injectable · injection | FRESENIUS | Prescription | 23 Jan 1981 |
| NUTRILIPID 20% | 20% | injectable · injection | B BRAUN | Prescription | 28 May 1993 |
| INTRALIPID 30% | 30% | injectable · injection | FRESENIUS | Prescription | 30 Dec 1993 |
| INTRALIPID 20% | 20% | injectable · injection | FRESENIUS | Prescription | 7 Aug 1996 |
| INTRALIPID 10% | 10% | injectable · injection | FRESENIUS | Discontinued | 7 Oct 1975 |
| TRAVAMULSION 10% | 10% | injectable · injection | BAXTER HLTHCARE | Discontinued | 26 Feb 1982 |
| SOYACAL 10% | 10% | injectable · injection | ALPHA THERA | Discontinued | 29 Jun 1983 |
| SOYACAL 20% | 20% | injectable · injection | ALPHA THERA | Discontinued | 29 Jun 1983 |
| LIPOSYN III 10% | 10% | injectable · injection | HOSPIRA | Discontinued | 24 Sep 1984 |
| LIPOSYN III 20% | 20% | injectable · injection | HOSPIRA | Discontinued | 25 Sep 1984 |
| NUTRILIPID 10% | 10% | injectable · injection | B BRAUN | Discontinued | 28 May 1993 |
| LIPOSYN III 30% | 30% | injectable · injection | HOSPIRA | Discontinued | 13 Jan 1998 |
| TRAVAMULSION 20% | 20% | injectable · injection | BAXTER HLTHCARE | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| INTRALIPID 20% | 02065673 | 20 % / W/V | EMULSION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
Safety signals and safety-related labeling changes
- US FDA 24 Jul 2025 KABIVEN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Jul 2025 PERIKABIVEN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Soybean oil
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.